Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ZEPOSIA (ozanimod)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ZEPOSIA (ozanimod)

Medicine - Posted on Feb 10 2023
Active substance (DCI)
  • ozanimod
history (3)
  • 1/18/23

    ZEPOSIA (ozanimod) - Sclérose en plaques

    Réévaluation. Recommandations particulières Compte tenu de la complexité de la prise en charge des SEP-R très actives, dans ...
    icône flèche
  • 6/29/22

    ZEPOSIA (ozanimod (chlorhydrate d')) - Rectocolite hémorragique (RCH)

    Key points Unfavourable opinion for reimbursement in the treatment of adult patients with moderately to severely active ulce...
    CAV :
    54321
    icône flèche
  • 12/2/20

    ZEPOSIA (ozanimod)

    Key points Favourable opinion for reimbursement in the treatment of adult patients with relapsing remitting multiple scleros...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L04AA38
Manufacturer
BRISTOL-MYERS SQUIBB
Presentation

ZEPOSIA 0,23 mg + 0,46 mg, gélule
Plaquette(s) PVC polychlortrifluoroéthylène aluminium de 7 gélule(s) (4 gélule(s) de 0,23 mg et 3 gélule(s) de 0,46 mg) (CIP : 34009 302 091 6 5)

ZEPOSIA 0,92 mg, gélule
Plaquette(s) PVC polychlortrifluoroéthylène aluminium de 28 gélule(s) (CIP : 34009 302 082 9 8)

All our publications
    Autoimmune diseases Central nervous system diseases Demyelinating diseases Drug therapy Esophageal and gastrointestinal diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mF1v2jAUhu/5FVHuSQi0hU6BamPthtSqjBZt2k1lkkMxC3Z6bPPRXz+H0I1OjroafBnbec+Jz+vHR4kv1ovMWwIKylnXj4KG7wFLeErZY9cf31/VO/5FrxbPyZLsLWsHjSBq+l6SESG6fjEbTIAwEfy4uf4M+n1Av1fzYj6ZQyJfrVOSZsFXImY3JC/WePGS09RbgJzxtOvnSm5HvVhI1Fn0Vhx/iZwkEIe7kf3Z+cPJ/ngcFmL/oaoE4DVhj0ZRYFaaiUIEJvtEwiPHTUW+LSttKkYguMIEhkTOhsiXNIXUGGJKMgFWQaar9A5wmYEsghjFw3myEFbiZE7WI3gamJP+qGf7ci3rjXrUPjlvthutThS1O1ahcG+rzFXQHxHmD61m86zVbITAwmfIuaCkzp8JowueWhZpyFGSzFF5qOi/dpijOAhPb9ogpSLPyCaYi9x2qwgSPQ2oOeDuQ4ovuEdNpkzv2T/6TGVZ+M6sxztuOMq4wFKfKyYr8HE1st2IPmcS1tUVtSOeXO+8SEEcT/aZMzPth2qS0cSWbZo+CoQcjwbVaHNChU9EwBjdYeE7ZSlfiePjZr+8jrLPt8Q0iuaYRg/N885ZdHpqfZp+ai9V3DmXCnkOoQYRFYfwZcCm/FCyaHuapV7MeXxfblsgnpAMKpqguiVttCFfejZnlnd3nMoJo+iXy3tbn3xTgJu77aNRmqbdPxW2Q7ELvmtXVib+fo+XR91Je6zQjJCZlLn4EIar1SqYEVEXRO9SMEV3rN+7Z9116U4u87K5KXnpKPVJeRG+r1S2R+6t6/7QFnb3/q5VNsaQqOCAWpR0dsbQweXxsfy3f3WW9vAVRtyF2faaRFLOXLU+amLuew66CHRd2RVqQNxOp7Tir0mlL+Ow/GPTq8Vh8bemV/sNx4HzLg==
K7rf5jU7mRxybFXp